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Background: The naturally-occurring omega (ω)-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid (EPA)
reduces colorectal adenoma (polyp) number and size in patients with familial adenomatous polyposis. The safety
profile and potential cardiovascular benefits associated with ω-3 PUFAs make EPA a strong candidate for colorectal
cancer (CRC) chemoprevention, alone or in combination with aspirin, which itself has recognized anti-CRC activity.
Colorectal adenoma number and size are recognized as biomarkers of future CRC risk and are established as
surrogate end-points in CRC chemoprevention trials.
Design: The seAFOod Polyp Prevention Trial is a randomized, double-blind, placebo-controlled, 2 × 2 factorial
‘efficacy’ study, which will determine whether EPA prevents colorectal adenomas, either alone or in combination
with aspirin. Participants are 55–73 year-old patients, who have been identified as ‘high risk’ (detection of ≥5 small
adenomas or ≥3 adenomas with at least one being ≥10 mm in diameter) at screening colonoscopy in the English
Bowel Cancer Screening Programme (BCSP). Exclusion criteria include the need for more than one repeat
endoscopy within the three-month BCSP screening period, malignant change in an adenoma, regular use of aspirin
or non-aspirin non-steroidal anti-inflammatory drugs, regular use of fish oil supplements and concomitant warfarin
or anti-platelet agent therapy. Patients are randomized to either EPA-free fatty acid 1 g twice daily or identical
placebo AND aspirin 300 mg once daily or identical placebo, for approximately 12 months. The primary end-point
is the number of participants with one or more adenomas detected at routine one-year BCSP surveillance
colonoscopy. Secondary end-points include the number of adenomas (total and ‘advanced’) per patient, the
location (left versus right colon) of colorectal adenomas and the number of participants re-classified as ‘intermediate
risk’ for future surveillance. Exploratory end-points include levels of bioactive lipid mediators such as ω-3 PUFAs,
resolvin E1 and PGE-M in plasma, urine, erythrocytes and rectal mucosa in order to gain insights into the
mechanism(s) of action of EPA and aspirin, alone and in combination, as well as to discover predictive biomarkers
of chemopreventive efficacy. The recruitment target is 904 patients.
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Colorectal cancer chemoprevention
The scientific and clinical rationale for prevention of colo-
rectal cancer (CRC) is firmly established [1]. CRC preven-
tion strategies include population screening, endoscopic
surveillance of high-risk groups, chemoprevention (the use
of drugs, vitamins or other food supplements), and health
education leading to lifestyle modifications such as weight
loss and physical activity [1].
The long natural history of human ‘sporadic’ colorectal
carcinogenesis, during which tumor initiation and benign
adenoma (or polyp) growth precede transformation into a
clinically apparent malignant adenocarcinoma (or cancer)
over a number of years, has been the basis for CRC
prevention strategies aimed at detection and removal of
asymptomatic colorectal adenomas in healthy individuals
(either directly by colonoscopy- or flexible sigmoidoscopy
(FS)-based screening [2], or indirectly via colonoscopy
prompted by faecal occult blood testing [1]). Colonoscopic
polypectomy has been demonstrated to reduce CRC mor-
tality [3]. However, risk reduction was approximately 50%
in the US National Polyp Study analysis [3] and ‘interval’
CRC during screening and surveillance programmes is in-
creasingly recognized [4]. Therefore, there is still an unmet
clinical need for safe and effective CRC chemoprevention,
in combination with existing screening and surveillance
programmes [5].Candidate CRC chemoprevention agents
There are several potential CRC chemoprevention agents
including non-steroidal anti-inflammatory drugs (NSAIDs),
hormone replacement therapy and micro-nutrient admin-
istration, e.g., folic acid, vitamin D [6]. The largest body of
evidence supports the use of the NSAID aspirin for CRC
chemoprevention [7]. However, aspirin has not yet been
advocated for primary or secondary CRC chemoprevention
due to continuing uncertainty about the optimal daily dose
(different trials have reported efficacy of either high-
(>300 mg) or low-dose (<100 mg) aspirin [7]) and the ab-
sence of a clearly defined at-risk population, in whom
benefit would outweigh the small risk of gastro-intestinal
and intra-cerebral bleeding associated with aspirin [7].
Combination therapy is widely recognized as a promising
strategy for CRC chemoprevention, particularly if the com-
bination of agents has other beneficial effects [8]. Omega
(ω)-3 polyunsaturated fatty acids (PUFAs) are attractive
candidate ‘natural’ CRC chemoprevention agents for evalu-
ation alone and in combination with aspirin, given thatboth agents also have proven cardiovascular benefits and
are already widely prescribed together following myocardial
infarction [9].
Omega-3 polyunsaturated fatty acids
Polyunsaturated fatty acids are important components of
the normal diet. Two classes of PUFAs, ω-6 and ω-3
PUFAs, are classified as essential in that they cannot be
readily synthesized in the human body and so must be
obtained from dietary sources [10]. The principal ω-3
PUFAs are C20:5 eicosapentaenoic acid (EPA) and C22:6
docosahexaenoic acid (DHA), which are found predomin-
antly in oily, cold-water fish such as mackerel, having en-
tered the food chain following synthesis by plankton [10].
However, in ‘western’ diets, ω-6 PUFAs predominate in-
cluding C20:4 arachidonic acid, which is the main substrate
for cyclooxygenase (COX) enzymes [10].
Anti-CRC activity of ω-3 PUFAs
There is a strong body of pre-clinical evidence that ω-3
PUFAs have anti-CRC activity [11]. Recently, high dietary
intake of marine-derived ω-3 PUFAs has been associated
with reduced colorectal adenoma risk [12]. Equivocal bene-
fit of ω-3 PUFA intake in some human observational stud-
ies may be related to methodological difficulties measuring
ω-3 PUFA or fish intake [10] and the fact that dietary ω-3
PUFA exposure may not be sufficient for consistent anti-
CRC activity in individuals consuming moderate amounts
of fish (a portion of oily fish 2–3 times per week only pro-
vides the equivalent of approximately 500 mg per day of
EPA and DHA combined) [10].
A 500 mg gastro-resistant capsule formulation of EPA
as the free fatty acid (FFA) is now available for adminis-
tration of large amounts of EPA, up to 2 g daily. EPA is
released from the capsules and absorbed maximally in
the small intestine, thereby minimizing gastrointestinal
side-effects. EPA as the free fatty acid (EPA-FFA) is sig-
nificantly better absorbed than EPA in the usual ethyl
ester or triglyceride forms [13].
EPA-FFA has recently been demonstrated to reduce
intestinal adenoma multiplicity by 79% in the ApcMin/+
mouse model of familial adenomatous polyposis (FAP)
[14]. This study led to a Phase III double-blind RCT of the
effect of treatment with EPA-FFA 2 g daily for 6 months
on rectal polyps in patients with FAP [15]. This trial has
provided the first definitive evidence of chemopreventive
efficacy of EPA in humans with a net decrease in adenoma
numbers and a cumulative reduction in adenoma size of
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cebo arms [15]. The percentage reduction in polyp burden
was similar to the anti-neoplastic activity previously ob-
served in FAP patients treated with the selective COX-2 in-
hibitor celecoxib [16], a drug which was subsequently
demonstrated to prevent ‘sporadic’ colorectal adenomas in
a polyp prevention trial [17].
Mechanisms of the anti-neoplastic activity of EPA
and aspirin
The precise mechanism(s) by which EPA and aspirin
have anti-CRC activity are not fully understood [10,18].
However, it is currently accepted that, even though these
agents are likely to act via both COX-dependent and -
independent mechanisms, modulation of COX activity
plays an important role in their anti-neoplastic effects.
EPA and aspirin are both potent inhibitors of COX-1
but they alter COX-2 activity in different ways leading to
production of different bioactive lipid mediators, includ-
ing PGE3 (EPA) and 15R-HETE (aspirin) [18]. Aspirin
irreversibly acetylates the COX enzymes leading to
conversion of EPA to 18R-hydroxyeicosapentaenoic acid
(18R-HEPE) and then trihydroxy-EPA, also known as
resolvin (Rv) E1, which has potent anti-inflammatory ac-
tivity [19]. Therefore, there is a biochemical basis for a
potential interaction between EPA and aspirin. The avail-
able clinical evidence suggests that the cardiovascular ef-
fects of EPA and aspirin are simply additive based on the
accumulated evidence of extensive use of dual therapy in
cardiology patients [9]. However, there is evidence for
both an additive and synergistic relationship between as-
pirin and ω-3 PUFAs from independent ex vivo human
platelet aggregation studies [20,21].
A polyp prevention trial using patients requiring
‘high risk’ colonoscopic surveillance
The adenomatous polyp, particularly the ‘advanced’
lesion (≥10 mm diameter, with tubulo-villous/villous
histology or with high-grade dysplasia), is an established
surrogate biomarker of CRC risk and has been used
consistently as a primary colonoscopic end-point in mul-
tiple short-term (up to 3 years) CRC chemoprevention
trials [17,22].
Previous polyp prevention trials have recruited pa-
tients that are roughly equivalent to ‘intermediate risk’
patients in the Bowel Cancer Screening Programme
(BCSP), which uses the same definition as the British
Society of Gastroenterology adenoma surveillance guide-
lines, i.e., 3–4 adenomas detected or at least one aden-
oma >10 mm in diameter [23]. The three-year total
adenoma recurrence rate in these polyp prevention trials
varied between 25–50% in the placebo arm [1,7,17,22].
Recruitment of ‘high risk’ (defined as ≥5 small adenomas
or ≥3 adenomas, with at least one being ≥10 mm indiameter) BCSP patients undergoing surveillance colon-
oscopy one year after the last complete screening colon-
oscopy [23] capitalizes on a higher adenoma recurrence
rate (>60%; unpublished data) at an earlier (12–15 month)
time-point, thus providing sample size benefits and re-
duced trial duration. Previous concerns about the use of
an approximate one-year end-point in polyp prevention
trials have been allayed by the observation that adenoma
outcomes at one year have consistently mirrored those
reported at later time-points [22].
Another methodological consideration relates to the
possible effect of ‘missed’ adenomas rather than ‘new’
lesions detected during short-term colonoscopic assess-
ment of ‘recurrence’. Preliminary data from the South of
Tyne and Tees BCSP Centres have demonstrated that one
or more adenomas (that can be assumed to be ‘missed’)
were detected in 36% of 44 high risk individuals who
underwent a check colonoscopy to assess a polypectomy
site within three months of the index colonoscopy, com-
pared with a 66.2% adenoma recurrence rate at one year.
This large difference in adenoma detection between 3 and
12 months supports the supposition that there is de novo
adenoma growth over a 12 month period and is mirrored
by data from a similar American study [24]. Moreover, 86%
of the ‘recurrent’ adenomas at one year in the South of
Tyne and Tees cohort were small, non-advanced aden-
omas (rather than ‘advanced’ lesions), which would be
expected if the majority of adenomas detected at this time-
point represented de novo adenoma growth. In practice,
short-term colonoscopic ‘recurrence’, even in expert hands,
represents a combination of ‘new’ and ‘missed’ adenomas.
Therefore, chemopreventive efficacy observed in RCTs is
likely to be a combination of polyp prevention and regres-
sion, a concept that has been readily accepted in ‘proof-of-
principle’ FAP RCTs [15,16]. Importantly, the reduction in
adenoma ‘recurrence’ in the aspirin polyp prevention RCTs
[22] has predicted the longer-term effect of aspirin on CRC
incidence [7], confirming the utility of adenoma recurrence
as a surrogate biomarker of CRC risk.
From 2013, FS screening (termed Bowel Scope in the
BCSP) will be offered to all people aged 55 years, with
self-referrals accepted up to the age of 60. National roll-
out across England is expected by 2016. Any patient
undergoing FS in the Bowel Scope programme, who
has a polyp ≥10 mm, ≥3 adenomas, an adenoma with a
tubulovillous or villous component, an adenoma with
high-grade dysplasia, or in whom polypectomy is not ap-
propriate at screening FS, will be referred for full screen-
ing colonoscopy. Adenoma outcomes will be summated
from the FS and subsequent full colonoscopy for the pur-
poses of risk stratification for future surveillance colonos-
copy. Therefore, FS screening provides another pathway
for identifying ‘high risk’ individuals who require one-
year surveillance colonoscopy.
Hull et al. Trials 2013, 14:237 Page 4 of 10
http://www.trialsjournal.com/content/14/1/237Aims of the seAFOod Polyp Prevention Trial
and hypotheses to be tested
The primary aim of the seAFOod Polyp Prevention Trial
is to determine whether the naturally-occurring ω-3
PUFA EPA, in the FFA form, prevents colorectal aden-
omas, either alone or in combination with aspirin.
The following primary hypotheses will be tested: i) EPA-
FFA 2 g daily is more effective than placebo for reduction
in adenoma recurrence; ii) Aspirin 300 mg daily is more ef-
fective than placebo for reduction in adenoma recurrence.
The secondary aim of the seAFOod Polyp Prevention
Trial is to assess the tolerability and safety of EPA in the
FFA form (EPA-FFA) alone and in combination with
aspirin.
Design
The seAFOod Polyp Prevention Trial is a randomized,
double blind, placebo-controlled, 2 × 2 factorial trial of
EPA-FFA 2 g daily and aspirin 300 mg daily.
Setting
The Trial is integrated into the English BCSP such that
participation in the Trial does not affect routine clinical
care in either the screening or surveillance phase of the
BCSP. The Trial was given Research Ethics Committee
(REC) approval by the NRES Committee East Midlands
(REC Reference 10/H0405/90). Approval for the Trial and
subsequent substantial protocol amendments were also
obtained from the English BCSP Research Committee.
The Trial is based in BCSP Centres, which comprise a
variable number of individual BCSP endoscopy sites, at
which patients are identified as ‘high risk’ and partici-
pants are randomised and followed-up prior to exit sur-
veillance colonoscopy one year later.
Colonoscopy quality assurance (QA) in the BCSP is
excellent [25]. Every BCSP colonoscopist must pass an
accreditation examination and maintain a caecal intub-
ation rate greater than 90% and an adenoma detection
rate greater than 35%, thus minimising operator variabil-
ity in Trial colonoscopy [25].
Participants
BCSP patients between 55–73 years old, identified as ‘high
risk’ (≥5 small adenomas or ≥3 adenomas, with at least one
being ≥10 mm in diameter) at the first complete screening
colonoscopy. Patients aged 74 years or above are excluded
as they would not automatically be offered surveillance col-
onoscopy by the BCSP if the proposed examination oc-
curred at an age in excess of 75 years of age.
Exclusion criteria are:
 Requirement for more than one repeat colonoscopy
or flexible sigmoidoscopy within the BCSP 3-month
screening window. Malignant change in an adenoma requiring Colorectal
Cancer Multi-disciplinary Team management.
 Regular (>3 doses per week) prescribed or ‘over the
counter’ (OTC) aspirin or regular (>3 doses per week)
prescribed or OTC non-aspirin NSAID use.
 Aspirin intolerance or hypersensitivity, including
aspirin-sensitive asthma.
 Active peptic ulcer disease within 3 months or
previous peptic ulcer (not on proton pump
inhibitor prophylaxis).
 Fish or seafood allergy.
 Current or planned regular (>3 doses per week) use
of fish oil supplements.
 Known clinical diagnosis or gene carrier of a
hereditary CRC predisposition (FAP, hereditary
non-polyposis colorectal cancer).
 Previous or newly diagnosed inflammatory bowel
disease.
 Previous or planned colorectal resection.
 Known bleeding diathesis or concomitant warfarin
therapy or use of any other anti-coagulant or
anti-platelet agent (e.g., Clopidogrel).
 Severe liver impairment.
 Severe renal failure (creatinine clearance <10 mL/min)
 Current methotrexate use at a weekly dose of 15 mg
or more.
 Inability to comply with study procedures and agents.
 Serious medical illness interfering with study
participation.
 Participant taking part in another interventional
clinical trial.
 Failure to give written informed consent.
Note that prior use of NSAIDs or a fish oil preparation
are not exclusions if they are self-prescribed, and not
recommended by a doctor, and the patient is willing to
stop the preparation for the duration of the Trial.
Intervention
Participants are randomised to one of four groups
according to a 2 × 2 factorial design in order to receive
gastro-resistant EPA-FFA 2 g daily per os (as 2 × 500 mg
ALFA™ capsules taken twice daily with food) or identical
placebo (capric and capryllic acid medium-chain trigly-
cerides), which are both kindly provided by SLA Pharma
AG [15] AND enteric-coated aspirin 300 mg daily per os
(as one 300 mg tablet taken with food) or identical pla-
cebo (both kindly provided by Bayer Pharma AG) until
the day before surveillance colonoscopy (Table 1).
Internet-based treatment assignment is determined by
a computer-generated pseudo-random code using ran-
dom permuted blocks of randomly varying size. Trial
participants are allocated with equal probability to each
treatment arm with stratification by BCSP Centre.
Table 1 seAFOod polyp prevention trial treatment
allocation
Placebo Placebo
EPA-FFA 1 g twice daily Placebo
Placebo Aspirin 300 mg once daily
EPA-FFA 1 g twice daily Aspirin 300 mg once daily
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Primary end-point
The number of participants with one or more adenomas
detected at the first BCSP surveillance colonoscopy.
Secondary end-points
i. The number of participants with one or more
‘advanced’ (≥10 mm diameter, high-grade dysplasia
or tubulo-villous/villous histology) adenomas at the
first BCSP surveillance colonoscopy.
ii. The number of ‘advanced’ adenomas per participant
at the first BCSP surveillance colonoscopy.
iii. The total number of adenomas per participant at
BCSP surveillance colonoscopy at the first BCSP
surveillance colonoscopy.
iv. The region of the colorectum (right colon – any
part of the colon proximal to the splenic flexure; left
colon – the rectum and the colon distal to the
splenic flexure) where adenomas are detected at the
first BCSP surveillance colonoscopy.
v. The number of ‘high risk’ participants re-classified
as ‘intermediate risk’ after the first BCSP
surveillance colonoscopy (BCSP risk stratification
at the first surveillance colonoscopy follows BSG
Guidelines [23] so that any individual that does
not continue to fulfil ‘high risk’ criteria is classified
as ‘intermediate risk’ for further colonoscopic
surveillance at three years).
vi. The number of participants with CRC detected prior
to, or at, the first BCSP surveillance.
vii. Adverse events, including clinically significant
bleeding episodes.
Exploratory end-points
An important component of the seAFOod Polyp Preven-
tion Trial is the measurement of levels of bioactive lipid
mediators such as ω-3 PUFAs, 18R-HEPE, RvE1 and
PGE-M in plasma, urine, erythrocytes and rectal mucosa
in order to gain insight into the mechanism(s) of ac-
tion of EPA and aspirin, alone and in combination, as
well as to discover predictive biomarkers of EPA and/
or aspirin chemoprevention efficacy. Laboratory bio-
marker studies are detailed in The seAFOod Polyp
Prevention Trial protocol for laboratory studies, which
is an Appendix to the main Trial protocol (www.eme.ac.uk/projectfiles/0910025protocol.pdf). All analyses will be
conducted at the Good Clinical Laboratory Practice York-
shire Experimental Cancer Medicine Centre laboratory,
the Institute of Cancer Therapeutics in Bradford, and the
Leeds Institute of Biomedical & Clinical Sciences.
Trial schedule
The detailed trial schedule is described in the full Trial
Protocol at the EME programme website (http://www.
eme.ac.uk/funded_projects/). Figure 1 is a summary of
the trial visits and interventions.
In brief, ‘high risk’ BCSP patients are identified imme-
diately at screening colonoscopy on the basis of aden-
oma number and (endoscopic) size, confirmed later by
the histopathology report. Patients are formally assessed
for eligibility by a BCSP Specialist Screening Practitioner
(SSP) or Research Nurse (RN) when the histological ad-
enoma size is available approximately 7–14 days after
screening colonoscopy. If the patient is eligible, written
informed consent is sought and obtained prior to ran-
domisation. A validated Food Frequency Questionnaire
(FFQ) is completed at baseline and at the end of the
Trial so that any change in dietary ω-3 PUFA intake
during Trial involvement can be determined [26]. Blood
and urine are obtained at baseline (visit 1), 6 months
(visit 4) and at (exit) surveillance colonoscopy (visit 6).
Rectal biopsies are obtained at (exit) surveillance colon-
oscopy. Biological sample handling and storage are de-
tailed in The seAFOod Polyp Prevention Trial Manual
of Biological Sample Standard Operating Procedures
(Additional file 1).
Participants receive Investigational Medicinal Product
(IMP) in 6 month blocks at visit 1 and visit 4 in order to
cover the 12 month period between screening colonos-
copy and ‘high risk’ surveillance colonoscopy. It should
be noted that participants who require a second colon-
oscopy within the stipulated three-month BCSP screen-
ing episode period require more than 12 months of IMP
because the timing of the surveillance colonoscopy is
usually set 12 months from the last complete examin-
ation of the colon (Figure 1). This is not relevant to par-
ticipants who need a repeat flexible sigmoidoscopic
examination or partial colonoscopy when the subsequent
colonoscopy is still set 12 months from the Trial entry
colonoscopy (Figure 1).
Safety and tolerability considerations
Although it is not expected [9], increased bleeding risk
associated with EPA-FFA alone, or in combination with
aspirin, has not previously been evaluated in a large
Phase III study. Therefore, we recommend that all par-
ticipants stop IMP 10 days prior to, and for 4 days after,
any invasive medical or surgical procedure taking place
during the intervention period. Concomitant aspirin
Figure 1 Schedule of visits in the seAFOod Polyp Prevention Trial. Trial interventions that are not part of routine BCSP care are in bold
and underlined.
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onoscopy so that IMP can continue until the day of
the (exit) surveillance colonoscopy.
Systematic review has not found any evidence of wors-
ening of glycaemic control in diabetics taking omega-3
preparations [27], although there is a report of short-
term loss of glycaemic control in diabetic patients taking
4 g EPA daily [28]. Trial participants with diabetes mellitus
are reminded to monitor their glycaemic control by the
usual means during the Trial.
Clinical studies indicate that EPA-FFA is well-tolerated at
doses up to 2 g per day over periods up to 6 months [15].
The principal undesirable effects are expressed throughthe gastrointestinal tract with diarrhoea, abdominal pain,
nausea and vomiting. These are normally relatively mild in
severity and can be minimised or removed by dosing with
food or dose reduction to 1 g daily [15]. If an adverse event
is thought to be related to IMP, the dose of EPA-FFA or
placebo can be temporarily reduced per protocol to 1 g per
day aiming to increase the dose back to 2 g daily within
2 weeks.
Sample size
The sample size estimate was based on the RCT of the
same dose and preparation of EPA-FFA in FAP patients
[15], a meta-analysis of aspirin RCTs [22] and detailed
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Tees BCSP Centres.
In order to detect a minimum 18% relative reduction
in adenoma risk in each two-arm comparison (less than
the 22% reduction in polyp number compared with
placebo in the FAP Trial [15] and below the absolute
reduction in polyp number at one year [38%] in the
aspirin RCTs [22]) from a 60% adenoma recurrence
rate (South of Tyne and Tees BCSP data) at surveil-
lance colonoscopy to 49%, 678 evaluable ‘high risk’ in-
dividuals need to be randomized equally to the four
treatment arms, with 80% power at a 5% two-sided sig-
nificance level. Standard practice for 2 × 2 factorial de-
signs in the assumed absence of any interaction bases
the sample size estimate on comparison ‘at the margins’
of active treatment A vs. placebo A (half of whom in
each arm receive active treatment B and the other half
placebo B). Assuming the same target effect size and
alpha, this yields the same power for the marginal com-
parison of active treatment B vs. placebo B (half of
whom in each arm receive active treatment A and the
other half placebo A). With a total sample size of 678
for analysis, there is, in fact, a slight reduction in power
(to 75%) which arises if both treatments work, because
then the overall comparison for treatment A is not 0.49
vs. 0.6, but is 0.445 vs. 0.545 (averaging over the pla-
cebo and treatment B arms). To keep power at 80% for
the above figures, 192 individuals are required per arm
(total 768 evaluable ‘high risk’ individuals). Allowing
for a 15% drop-out rate increases the sample size to
768/0.85 = 904 individuals.
Data from the South of Tyne and Tees BCSP Centres
indicated that 20% of ‘high risk’ patients were expected
to be using aspirin, and thus be ineligible for the trial.
An allowance was made for an additional 20% of ‘high
risk’ patients to be ineligible due to other reasons. Based
on the assumption that 40% of patients would be ineli-
gible it was calculated that a total of 904/0.6 = 1,507
‘high risk’ patients would need to be identified at BCSP
screening colonoscopy. Trial timelines were based on
BCSP data suggesting that a BCSP Centre identifies
approximately 50 ‘high risk’ patients per year. On this
basis, the Trial intervention period was predicted to be
2 years and require 15 BCSP Centres (approximately 30
BCSP endoscopy sites).
Statistical analysis
The main approach to analyses will be intention-to-treat
(ITT), where the ITT population consists of all randomised
participants. No adjustment for multiple significance test-
ing was made in the sample size estimate or will be in the
analyses. Results of comparative analyses will be presented
as the appropriate point estimate (for example, risk ratio or
difference in means), 95% confidence interval and P value.No formal interim analysis for efficacy is planned and
hence there are no ‘stopping rules’.
Descriptive analyses
The baseline comparability of the groups will be
assessed with regard to the following variables: age at
randomization, gender, body mass index, cigarette smok-
ing, alcohol consumption, diagnosis of diabetes, require-
ment for a repeat colorectal endoscopic procedure within
3 months, number of adenomas detected at baseline,
number of ‘advanced’ adenomas detected at baseline and
the location of adenomas in the colorectum. Categor-
ical (including binary) variables will be summarized by
reporting numbers and percentages in each category, con-
tinuous variables will be summarized using means and
standard deviations. Missing data will be tabulated.
Primary analyses
For the primary outcome, it is anticipated that the 2 × 2
factorial trial will be analysed by an ‘at the margins’ ap-
proach, after first examining whether there is any evi-
dence of an interaction between EPA and aspirin [29],
although it is recognized that this will lack power to de-
tect anything but a very large interaction effect. The log
relative risk will be estimated using a log-binomial re-
gression model with robust standard errors to allow for
potential non-independence of observations within a BCSP
centre. Both interventions will be fitted simultaneously and
in a further secondary analysis, adjusted for ‘repeat colo-
rectal endoscopic procedure within 3 months required’
plus any other covariates identified as important from the
baseline comparisons. Should there be strong evidence of
an interaction between EPA and aspirin, the effect of each
treatment alone will be examined using an ‘inside the table’
approach, although it is recognized that precision for these
analyses may be reduced since each uses only approxi-
mately 50% of the available sample.
A per-protocol analysis will be conducted as a sensitiv-
ity analysis, where the per-protocol population consists
of all randomized participants who were not deemed to
have a protocol violation. Additionally, some BCSP cen-
tres consist of multiple hospitals (sites), therefore an
additional sensitivity analysis will be conducted in which
both BCSP centre and site will be treated as random ef-
fects in a multi-level model.
Secondary analyses
All secondary end-points will be analysed using the ITT
population, with the exception of adverse events, for which
we will analyse the safety population, consisting of all par-
ticipants who received at least one dose of trial medication.
 The relative recurrence of ‘advanced’ adenoma
detected at the first BCSP surveillance colonoscopy
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model with robust standard errors to estimate the
log relative risk.
 Number of ‘advanced’ adenomas per participant at
the first BCSP surveillance colonoscopy will be
analysed using a Poisson regression model with
robust standard errors.
 Number of adenomas per participant at the first
BCSP surveillance colonoscopy will be analysed
using a Poisson regression model.
 The region of the colorectum where adenomas are
detected at the first BCSP surveillance colonoscopy
will be explored, possibly using a Poisson random
effects model with bivariate response (corresponding
to polyp counts in the left and right colon) in which
treatment and a baseline polyp count will be
independent variables together with random intercepts
corresponding to patient and BCSP Centre.
 The number of ‘high risk’ participants re-classified
as ‘intermediate risk’ after the first BCSP
surveillance colonoscopy will be analysed using
binary regression or logistic regression, treating
centre as a random effect.
 The number of participants with CRC detected
prior to or at the first BCSP surveillance will be
analysed descriptively, and possibly using a logistic
regression model depending on numbers with this
outcome, although it is anticipated that there will be
low power due to small numbers.
Adverse events, including clinically significant bleeding
episodes will be summarized by tabulating the number
(and percentage) of events occurring in each treatment
arm. All participants who receive at least one dose of
treatment will be included in the safety analysis. Mis-
randomised participants will be analysed as treated.
Adverse drug reactions (ADRs) will be summarized by se-
verity using the preferred term and the worst severity and
causality recorded. The worst case will be assumed if sever-
ity or causality are missing. All participants who experience
treatment-emergent ADRs will be listed including partici-
pant identification, treatment arm, system organ class, pre-
ferred term, unexpectedness, seriousness, severity, start
and stop dates/times, action taken and outcome.
Discussion
The first patient first visit (FPFV) of the Trial was 11th
November 2011. It soon became clear from screening
logs at individual BCSP sites that the eligibility rate was
15–20% rather than the 60% that had been predicted in
the original sample size calculation. One contributing
factor was the use of other non-aspirin anti-platelet
agents such as clopidogrel, which we later added as
an extra exclusion criterion (Protocol version 3.1 dated12 Jan 2012), in order to completely rule out the possibil-
ity of excess bleeding risk due to concomitant use of
three agents with anti-platelet activity in one arm of the
Trial. Another major contributing factor was the larger
than expected number of ‘high risk’ individuals (approxi-
mately 25%) who required a repeat endoscopy, which was
an exclusion criterion in earlier versions of the Trial
protocol. We obtained data on the proportion of ‘high
risk’ patients undergoing a repeat endoscopic procedure
from participating BCSP sites and demonstrated that
there had been a consistent increase in the number of pa-
tients undergoing repeat ‘re-look’ procedures since the
start of the BCSP in 2006 and that ‘re-look’ rates varied
significantly across BCSP sites. ‘High risk’ patients, who
require a repeat screening procedure, were originally ex-
cluded from the Trial on the basis that the primary end-
point might be confounded by adenoma detection and re-
moval at an extra endoscopic procedure in-between the
screening and one-year surveillance procedures. However,
subsequent analysis (in April 2012) of the North-East
BCSP Hub (9 BCSP Centres) and the Southern BCSP Hub
(17 BCSP Centres) data on ‘high risk’ patients who under-
went one-year surveillance colonoscopy in 2010 did not
support this notion. Of 1,189 ‘high risk’ patients, 930 (78%)
went straight to one-year surveillance after a single screen-
ing colonoscopy. One or more adenomas were detected in
465 (63%) of 738 patients, for whom data were available.
The corresponding adenoma detection rate for ‘high risk’
patients, who underwent a repeat partial colonoscopy or
flexible sigmoidoscopy within 3 months of the initial
screening colonoscopy was 54% (59/110), but the adenoma
detection rate in patients who underwent a repeat full col-
onoscopy was 67% (56/83). The overall adenoma detection
rate at first surveillance colonoscopy was 62%, which is
consistent with the value (60%) used in our original sample
size calculation, although the cohort included patients who
had undergone a repeat screening endoscopy. Therefore,
we amended the protocol in order to allow recruitment of
those individuals who require no more than one repeat
endoscopic procedure (either colonoscopy or flexible sig-
moidoscopy) within the 3-month screening episode win-
dow (Protocol version 4.0 dated 24 May 2012).
At the time of the latest sample size estimate in April
2012, we assumed that drop-out would be 10% rather
than 15% (based on existing BCSP Trial site experience)
and noted that 27 participants had already been recruited
meaning that a further (768/0.9 = 853) – 27 = 826 partici-
pants were required. Data from the first 5 months’ re-
cruitment experience and from the above 2010 BCSP
Hub data indicated that approximately 24% of ‘high risk’
patients underwent a repeat endoscopy within 3 months
of the first screening colonoscopy and that 27% of ‘high
risk’ patients who were excluded because of the need for
a repeat colorectal endoscopic procedure also met an
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that the percentage recruitment could be increased from
15% (the current percent recruitment rate) to 15% +
17.5% (24% × 0.73) = 32.5%. Rounding the recruitment
rate down to 30%, we estimated that the remaining num-
ber of ‘high risk’ individuals that would need to be
screened from April 2012 to obtain 768 evaluable ‘high
risk’ individuals is 827/0.3 = 2,757.
Revised Trial timelines are currently based on an overall
‘high risk’ patient recruitment rate of 30% and identifica-
tion of approximately 50 ‘high risk’ patients by a BCSP
Centre per year (this estimate has been confirmed by our
data on the number of ‘high risk’ patients screened for the
Trial by open, participating Centres, so far). In order to
compensate, for the reduced percentage recruitment esti-
mate, the number of participating BCSP Centres has been
increased from 15 to 30 (equivalent to approximately 60
separate BSCP endoscopy sites throughout England).
The ability to recruit patients who have been identified
as ‘high risk’ via FS screening, as well as by faecal occult
blood test screening, should also increase the recruit-
ment rate of the Trial, as the Bowel Scope programme is
rolled out across England over the next two years.
The seAFOod Polyp Prevention Trial is the first Clinical
Trial of an Investigational Medicinal Product (CTIMP) in
the BCSP. The experience gained from the set-up and
intervention phases of the Trial will be invaluable for the
design of subsequent intervention trials in the BCSP. Early
experience has confirmed that the BCSP is an excellent
framework for a CRC chemoprevention RCT.
Trial status (1/7/2013)
The Trial is active and recruiting patients from 59 BCSP
sites (see Additional file 2).
Trial website: http://www.seafood-trial.co.uk/
The full Trial protocol is available at http://www.eme.
ac.uk/funded_projects/
Trial Co-ordinating Centre
Nottingham Clinical Trials Unit, Nottingham Health
Science Partners, C Floor South Block, Queens Med-
ical Centre, Nottingham, NG7 2UH, United Kingdom
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